Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Research & Development: 2016-2024

Historic Research & Development for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $240.2 million.

  • Crinetics Pharmaceuticals' Research & Development rose 46.13% to $90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.6 million, marking a year-over-year increase of 43.07%. This contributed to the annual value of $240.2 million for FY2024, which is 42.50% up from last year.
  • Crinetics Pharmaceuticals' Research & Development amounted to $240.2 million in FY2024, which was up 42.50% from $168.5 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Research & Development high stood at $240.2 million for FY2024, and its period low was $57.0 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $168.5 million (2023), whereas its average is $179.6 million.
  • Data for Crinetics Pharmaceuticals' Research & Development shows a peak YoY soared of 54.56% (in 2022) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Research & Development (Yearly) stood at $57.0 million in 2020, then surged by 47.82% to $84.3 million in 2021, then soared by 54.56% to $130.2 million in 2022, then climbed by 29.41% to $168.5 million in 2023, then skyrocketed by 42.50% to $240.2 million in 2024.